Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Watch a 1-hour webinar from the 2018 Antibody Engineering & Therapeutics Digital Week titled, “Emerging Technologies for Finding Rare Antibodies,” featuring scientists from Berkeley Lights and Teva Pharmaceuticals.
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.